Long-term efficacy and safety of exemestane in the treatment of breast cancer

Patient Preference and Adherence

Volumn 7, Issue , 2013, Pages 245-258

  Walker, G A ^a   Xenophontos, M ^a   Chen, L C ^a   Cheung, K L ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Adherence; Adjuvant; Breast cancer; Exemestane; Metastatic; Review

Indexed keywords

ANASTROZOLE; CELECOXIB; CYCLOPHOSPHAMIDE; DOXORUBICIN; EVEROLIMUS; EXEMESTANE; FULVESTRANT; LETROZOLE; MEGESTROL ACETATE; PLACEBO; ROFECOXIB; TAMOXIFEN;

ABDOMINAL PAIN; ADJUVANT THERAPY; ALOPECIA; ANEMIA; ANGINA PECTORIS; ANOREXIA; ANXIETY; ARTHRALGIA; ARTHRITIS; ARTHROPATHY; BONE DENSITY; BONE PAIN; BRAIN INFARCTION; BREAST CANCER; BREAST DISEASE; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CARPAL TUNNEL SYNDROME; CEREBROVASCULAR ACCIDENT; CONSTIPATION; COUGHING; DEEP VEIN THROMBOSIS; DEPRESSION; DIARRHEA; DIGESTIVE SYSTEM ULCER; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; EMBOLISM; ENDOCRINE DISEASE; ENDOMETRIAL DISEASE; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FATIGUE; FOOT PAIN; FRACTURE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEARTBURN; HOT FLUSH; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCREASED APPETITE; INFECTION; INSOMNIA; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LETHARGY; LEUKOPENIA; LIBIDO DISORDER; LIMB PAIN; LIVER FUNCTION TEST; MALAISE; MENOPAUSAL SYNDROME; META ANALYSIS (TOPIC); MOOD DISORDER; MUSCLE CRAMP; MUSCLE DISEASE; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NERVE COMPRESSION; NEUROLOGIC DISEASE; NEUTROPENIA; OCCLUSIVE CEREBROVASCULAR DISEASE; OSTEOARTHRITIS; OSTEOPOROSIS; PAIN; PARESTHESIA; PATIENT COMPLIANCE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHLEBITIS; POSTMENOPAUSE BLEEDING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSORY DYSFUNCTION; SIDE EFFECT; SKIN DISEASE; SLEEP DISORDER; SWEATING; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; URINARY DYSFUNCTION; UROGENITAL TRACT DISEASE; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINAL DRYNESS; VASCULAR DISEASE; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VOMITING; VULVOVAGINAL DISEASE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84875696820     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S42223     Document Type: Review

References (50)

1. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol. 2000;18(7):1399-1411.
2. Falandry C, Debled M, Bachelot T, et al. Celecoxib and exemestane verus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. Breast Cancer Res Treat. 2009;116(3):501-508.
3. Dirix LY, Ignacio J, Nag S, et al. Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib. J Clin Oncol. 2008;26(8): 1253-1259.
4. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(1):1092-1102.
5. Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008;26(10):1664-1670.
6. Mauriac L, Romieu G, Bines J. Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial. Breast Cancer Res Treat. 2009;117(1):69-75.
7. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520-529.
8. Paridaens RJ, Dirix L, Beex L, et al. Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen control. Clin Breast Cancer. 2000;1 Suppl 1:S19-S21.
9. Paridaens R, Dirix L, Lohrisch C, et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol. 2003;14(9):1391-1398.
10. Paridaens RJ, Dirix LJ, Beex LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol. 2008;26(30):4883-4890.
11. Llombart-Cussac A, Ruiz A, Anton A, et al. Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-2003 phase 2 randomized trial. Cancer. 2012;118(1):241-247.
12. Van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomized phase 3 trial. Lancet. 2011;377(9762):321-331.
13. Dowsett M, Cuzick J, Wale C, et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol. 2005;23(30):7512-7517.
14. Bartlett JMS, Brookes CL, Robson T, et al. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol. 2011;29(12):1531-1538.
15. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350(11):1081-1092.
16. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369(9561):559-570.
17. Bliss JM, Kilburn LS, Coleman RE, et al. Disease-related outcomes with long-term follow-up: an updated analysis of the Intergroup Exemestane Study. J Clin Oncol. 2012;30(7):709-717.
18. Mamounas EP, Jeong JH, Wickerham DL, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trials. J Clin Oncol. 2008;26(12):1965-1971.
19. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomized trial. Lancet. 2012;pii: S0140-6736(12)61963-61961.
20. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomized trials. Lancet. 2005;365(1):1687-1717.
21. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97(17):1262-1271.
22. Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype - ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342-2349.
23. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15(7):2483-2493.
24. Chow LW, Yip AY, Loo WT, Lam CK, Toi M. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol. 2008;111(1-2):13-17.
25. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361(9354):296-300.
26. Goss PE, Ingle JN, Ales-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364(25): 2381-2391.
27. Atalay G, Dirix L, Biganzoli L, et al. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients.' Ann Oncol. 2004;15(2):211-217.
28. Fallowfield LJ, Bliss JM, Porter LS, et al. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol. 2006;24(6):910-917.
29. Fallowfield LJ, Kilburn LS, Langridge C, et al. Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation. Br J Cancer. 2012;106(6):1062-1067.
30. Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomized controlled study. Lancet Oncol. 2007;8(2):119-127.
31. Gonnelli S, Cadirni A, Caffarelli C, et al. Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. Bone. 2007;40(1):205-210.
32. Geisler J, Lonning PE, Krag LE, et al. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. Eur J Cancer. 2006;42(17):2968-2975.
33. Bertelli G, Hall E, Ireland E, et al. Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES) - a randomized controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen. Ann Oncol. 2010;21(3):498-505.
34. Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. Lancet Oncol. 2012;13(4):420-432.
35. Jones SE, Cantrell J, Vukelja S, et al. Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicener trial substudy. J Clin Oncol. 2007;25(30): 4765-4767.
36. Kieback DG, Harbeck N, Bauer W, et al. Endometrial effects of exemestane compared to tamoxfien within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: results of a prospective gynecological ultrasound substudy. Gynecol Oncol. 2010;119(3):500-505.
37. Markopoulos C, Polychronis A, Dafni U, et al. Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek sub-study. Ann Oncol. 2009;20(1):49-55.
38. Markopoulos C, Dafni U, Misitzis, et al. Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy. Breast Cancer Res. 2009;11(3):R35.
39. Hozumi Y, Suemasu K, Takei H, et al. The effect of exemestane, anastrazole and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study. Ann Oncol. 2011;22(8): 1777-1782.
40. Hadji P, Ziller M, Kieback DG, et al. Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: results of a German 12-month, prospective, randomized substudy. Ann Oncol. 2009;20(7):1203-1209.
41. Hadji P, Ziller M, Kieback DG, et al. The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial. Breast. 2009;18(3):159-164.
42. Schilder CM, Eggens PC, Seynaeve C, et al. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM side-study. Acta Oncol. 2009;48(1):76-85.
43. Schilder CM, Seynaeve C, Beex LV, et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol. 2010;28(8):1294-1300.
44. Goss PE, Hadji P, Subar M, et al. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. Breast Cancer Res. 2007;9(4):R52.
45. Cigler T, Richardson H, Yaffe MJ, et al. A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women. Breast Cancer Res Treat. 2011;126(2):453-461.
46. Cheung AM, Tile L, Cardew S, et al. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol. 2012;13(3):275-284.
47. Reid DM, Doughty J, Eastell R, et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK expert group. Cancer Treat Rev. 2008;34 Suppl 1:S3.
48. Sedjo RL, Devine S. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat. 2011;125(1):191-200.
49. Henry NL, Desta Li L, Nguyen AT, et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol. 2012;30(9):936-942.
50. Van de Water W, Bastiaannet E, Hille ET, et al. Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: a TEAM study analysis. Oncologist. 2012;17(1):55-63.